Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer
Objective To investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with advanced epithelial ovarian cancer (EOC). Methods A retrospective study was performed, enrolling 33 patients with advanced EOC who failed standard systematic therapy. All patients were admini...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-10-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0211 |
| _version_ | 1828316250654113792 |
|---|---|
| author | JIN Huimin LIN Lihong ZHAO Zhen GONG Xishuang |
| author_facet | JIN Huimin LIN Lihong ZHAO Zhen GONG Xishuang |
| author_sort | JIN Huimin |
| collection | DOAJ |
| description | Objective To investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with advanced epithelial ovarian cancer (EOC). Methods A retrospective study was performed, enrolling 33 patients with advanced EOC who failed standard systematic therapy. All patients were administered with anlotinib combined with PD-1 blockades. The efficacy and safety profile were determined during treatment. Results The objective response rate of the 33 patients was 36.4% (95%CI: 20.4%-54.9%) and the disease control rate of the patients was 81.8% (95%CI: 64.5%-90.0%). The median PFS and OS of the 33-patient cohort were 7.6 months (95%CI: 3.1-12.1) and 19.6 months (95%CI: 15.1-24.1), respectively. The most common treatment-related adverse reactions were fatigue (66.7%), nausea and vomiting (54.5%), hypertension (48.5%), and diarrhea (39.4%). Furthermore, multivariate Cox regression analysis indicated that ECOG performance status and FIGO stage were independent factors for predicting the PFS of the combination regimen for patients with advanced EOC. Conclusion Anlotinib combined with PD-1 blockades preliminarily exhibit satisfactory efficacy and tolerable safety profile for patients with advanced EOC. |
| first_indexed | 2024-04-13T17:10:45Z |
| format | Article |
| id | doaj.art-3860c5a9dcac405aafff563cd331f1d7 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-13T17:10:45Z |
| publishDate | 2022-10-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-3860c5a9dcac405aafff563cd331f1d72022-12-22T02:38:17ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782022-10-0149101059106410.3971/j.issn.1000-8578.2022.22.02118578.2022.22.0211Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian CancerJIN Huimin0LIN Lihong1ZHAO Zhen2GONG Xishuang3Department of Gynecology, Anyang Tumor Hospital, Anyang 455000, ChinaDepartment of Gynecology, Anyang Tumor Hospital, Anyang 455000, ChinaDepartment of Gynecology, Anyang Tumor Hospital, Anyang 455000, ChinaDepartment of Gynecology, Anyang Maternal and Child Health Hospital, Anyang 455000, ChinaObjective To investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with advanced epithelial ovarian cancer (EOC). Methods A retrospective study was performed, enrolling 33 patients with advanced EOC who failed standard systematic therapy. All patients were administered with anlotinib combined with PD-1 blockades. The efficacy and safety profile were determined during treatment. Results The objective response rate of the 33 patients was 36.4% (95%CI: 20.4%-54.9%) and the disease control rate of the patients was 81.8% (95%CI: 64.5%-90.0%). The median PFS and OS of the 33-patient cohort were 7.6 months (95%CI: 3.1-12.1) and 19.6 months (95%CI: 15.1-24.1), respectively. The most common treatment-related adverse reactions were fatigue (66.7%), nausea and vomiting (54.5%), hypertension (48.5%), and diarrhea (39.4%). Furthermore, multivariate Cox regression analysis indicated that ECOG performance status and FIGO stage were independent factors for predicting the PFS of the combination regimen for patients with advanced EOC. Conclusion Anlotinib combined with PD-1 blockades preliminarily exhibit satisfactory efficacy and tolerable safety profile for patients with advanced EOC.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0211epithelial ovarian canceranlotinibpd-1 blockadeefficacyadverse effect |
| spellingShingle | JIN Huimin LIN Lihong ZHAO Zhen GONG Xishuang Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer Zhongliu Fangzhi Yanjiu epithelial ovarian cancer anlotinib pd-1 blockade efficacy adverse effect |
| title | Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer |
| title_full | Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer |
| title_fullStr | Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer |
| title_full_unstemmed | Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer |
| title_short | Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer |
| title_sort | efficacy and safety of anlotinib combined with pd 1 blockades for patients with advanced epithelial ovarian cancer |
| topic | epithelial ovarian cancer anlotinib pd-1 blockade efficacy adverse effect |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0211 |
| work_keys_str_mv | AT jinhuimin efficacyandsafetyofanlotinibcombinedwithpd1blockadesforpatientswithadvancedepithelialovariancancer AT linlihong efficacyandsafetyofanlotinibcombinedwithpd1blockadesforpatientswithadvancedepithelialovariancancer AT zhaozhen efficacyandsafetyofanlotinibcombinedwithpd1blockadesforpatientswithadvancedepithelialovariancancer AT gongxishuang efficacyandsafetyofanlotinibcombinedwithpd1blockadesforpatientswithadvancedepithelialovariancancer |